Zymeworks (NYSE:ZYME – Get Free Report) and Enveric Biosciences (NASDAQ:ENVB – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.
Analyst Ratings
This is a summary of recent ratings and target prices for Zymeworks and Enveric Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zymeworks | 0 | 1 | 3 | 0 | 2.75 |
| Enveric Biosciences | 0 | 0 | 1 | 0 | 3.00 |
Zymeworks presently has a consensus price target of $14.75, indicating a potential upside of 17.62%. Enveric Biosciences has a consensus price target of $10.00, indicating a potential upside of 1,896.01%. Given Enveric Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Enveric Biosciences is more favorable than Zymeworks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Zymeworks | -179.42% | -21.97% | -17.26% |
| Enveric Biosciences | N/A | -260.30% | -164.11% |
Risk and Volatility
Zymeworks has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
Valuation & Earnings
This table compares Zymeworks and Enveric Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zymeworks | $76.01 million | 11.72 | -$118.67 million | ($1.79) | -7.01 |
| Enveric Biosciences | N/A | N/A | -$17.29 million | ($6.41) | -0.08 |
Enveric Biosciences has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 1.2% of Zymeworks shares are owned by insiders. Comparatively, 1.2% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Zymeworks beats Enveric Biosciences on 8 of the 13 factors compared between the two stocks.
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
About Enveric Biosciences
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
